Services Overview

We act as your agent, representative, interim or mentor/coach. We can set up your company in Japan. We are dedicated to making your commercial success real!

We supply the market intelligence you need to be successful in Japan!

We connect you with the right Japanese companies within Biopharma, ATMP, CGT, Regenerative Medicine, Pharmaceuticals, Combination Devices, IVD’s, Universities and distributors. The right mix you need among: Trade Shows, KOLs, customers, partners, distributors . . .

A handshake under the Rising Sun of Japan.

Biosector = Commercialization in Japan

Preparation and reports – What you need to know!

We produce your feasibility studies and all other types of reports that you need to unlock your commercial pathway into Japan’s Pharmaceutical Industry. We help pave every step of your commercialization process.

Download for free:

You need: fast, accurate and actionable reports, feasibility studies, target lists and analysis to be able to draw up the best strategies.

We supply: just that!

By partnering with Biosector, you get the upper hand!

Market Entry: Seamless Integration and Strategic Positioning

Your success in Japan requires the following keys:

  1. Budget
  2. Cultural competence
  3. Clear goals
  4. Strategic approach
  5. Feet on the ground
  6. Long term mindset
  7. Patience
  8. Consistency


We make sure you are moving as fast as possible and that your expectations are aligned with those of your future clients and partners’ in Japan.

Market Expansion: Optimizing Your New Commercial Opportunities and Accelerating Growth

Expanding your footprint in Japan is crucial. Accelerating your growth successfully equals long-term success. You need competence and excellence: we supply! You need to optimize your new avenues for growth – we support you! We assist you in making sure of your new market segments and their strategies.

Leveraging your opportunities through our extensive industry connections is a valuable shortcut.

With Biosector, you have the advantage that only comes with exceptional professionals. Every step of the way.

About Stefan Sandström 

CEO of Biosector Ltd. Residence

Residence: Based in Metropolitan Tokyo since 2007.

Unique Perspective: Science and business.

Education: Medicine and chemical engineering.

Leadership: Successfully led multiple industrial companies as CEO.

Accreditations: Accredited business consultant via  German RKW.

Collaborations: Japanese partner to notable entities:  SPECTARIS and Kalms Consulting.

Recognitions: Appointed as an expert on conducting business in Japan by the EU-Japan Centre for Industrial Cooperation.

Track Record: Three decades of experience in international and cross-border business development, achieving first sales.

Passion: Kendo (martial art) with the rank of 6 dan.

Testimonials/Cases

Dan Spacie

CEO of MAP Patient Access, UK

”I have worked with Stefan Sandström outside of Biosector for over a year and will continue to work with him in Biosector. This is an exceptionally highly skilled partner, walking the extra mile and having made all the difference for building our traction in Japan.”

Anne-Kathrin Schmalz

Senior Manager Foreign Trade and Export Promotion

”Mr Sandström delivered an amazing seminar for our members in Sep 2021. He combined extensive specialist knowledge of the Japanese bio and laboratory market and how to bridge cultural differences. ”

Tony White

“Biosector’s business intelligence has helped me identify investment opportunities I would never have discovered. They deliver incisive analysis applying the Pareto Principle, allowing me to make fast decisions and save huge amounts of time. A great help for guiding the next steps forward.” – Tony White, founder of BioPhorum and angel investor

Blog

An editorial infographic-style image, rendered in a highly detailed photorealistic illustration, shows multiple elevated railway tracks merging. One set of tracks, labeled with rusty signs for various local development milestones, curves into a main line labeled with a large overhead sign, 'GLOBAL DEVELOPMENT / MRCT (MULTI-REGIONAL CLINICAL TRIALS)'. Modern Japanese Shinkansen trains, including one with 'Phamaraxt' livery, travel on the main line. The scene is set in a daylight Yokohama cityscape, with skyscrapers and industrial buildings. Smaller rusty milestone signs date progress: 'DEC 2023 Phase I flexibility', 'OCT 2024 Rare-disease flexibility', 'JUN 2025 Clinical-trial reform', 'FEB 2026 One-stop service + PMDA', 'JUN 2026 Single IRB', and a final 'AUG 2026 Japan earlier in global development'. A main sign in the foreground left labels the converging tracks 'SEPARATE JAPANESE DEVELOPMENT'.
Japan changed important parts of its clinical development system in December 2023, when the Ministry of Health, Labour and Welfare, MHLW, introduced new principles governing the need for Japanese Phase I studies before participation in multi-regional clinical trials. That was the beginning, not the end Since […]
Stefan speaking on stage at a pharmaceutical industry conference, in front of a large presentation screen about Daiichi Sankyo, antibody-drug conjugates, and new business opportunities in oncology.
Daiichi Sankyo has built one of the pharmaceutical industry’s most productive antibody-drug conjugate platforms. Enhertu has changed treatment across several HER2-expressing cancers. Datroway has extended the company’s reach into TROP2-directed therapy. A further group of clinical candidates is moving through solid tumours and haematological malignancies. The […]
A photorealistic illuminated billboard beside a wet city road at dusk, displaying: "Otsuka's new target is to hit ¥3.5 trillion by 2035."
Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to hit ¥3.5 trillion by 2035 represents a concrete capital allocation roadmap. Between now and 2035, Otsuka will need specialised capabilities, from ADC manufacturing to digital phenotyping, that it cannot build […]
A man in a dark suit stands and points at a large projection screen with Japanese text and "LIFE SCIENCES LAB" graphics, inside a high-rise office overlooking the Tokyo skyline and Tokyo Tower. A seated audience, including people in lab coats, listens.
This article: Japan market entry can produce meetings, contacts and polite interest without producing commercial traction. This practical framework explains how life science companies can validate the opportunity, select the right route, map Japanese accounts, qualify interest and build a functioning commercial process. Can be used […]
A high-angle photograph shows several people's hands working together to assemble a large, cardboard jigsaw puzzle on a light-colored wooden table surface. The central hub of the puzzle is a circular piece clearly labeled with "Tanabe Pharma". Other interlocking pieces are being added around it. One large piece on the upper right is labeled "Shionogi", and connected to it is a piece labeled "Radicava". On the lower left, a piece is labeled "Towa Pharma", and it is connected to a smaller, specific piece labeled "17 legacy drugs", which also connects back to the Tanabe hub. Other blank, unassembled puzzle pieces are scattered around the main assembly area, and blurred window frames are visible in the background. At least four or five separate hands are visible, representing different individuals or entities, suggesting multi-party cooperation or negotiation. The lighting is soft and even, highlighting the textures of the hands and the cardboard pieces.
Japan’s pharmaceutical ecosystem is seemingly undergoing a profound structural shift. If you are targeting the Japanese market from the bio-side of the industry, you need fast, accurate, and actionable intelligence to navigate this ever-changing landscape. The recent carve-out of Tanabe Pharma’s traditional Fully Integrated Pharmaceutical Company […]
A conceptual illustration of an hourglass with a human brain at the top, releasing a cascade of binary code (1s and 0s) and data symbols. At the bottom red bulb, two robotic hands are analyzing and sorting this data into categories marked by red checkmarks and black cross-marks. A factory and cherry blossoms are in the background.
The biopharma world is still processing the seismic news of Isomorphic Labs’ $2.1 billion Series B funding round. Led by Thrive Capital and backed by a geopolitical coalition including Alphabet, Temasek, MGX, and the UK Sovereign AI Fund, this is the largest venture round the sector […]

Please feel warmly welcome to contact us:

email: info@biosector.jp
phone: +81 80-3404-8431

Address: Yokohama Landmark Tower, 20th Floor, 2-2-1 Minatomirai, Nishi-ku, 〒220-8120,

Yokohama, JAPAN

Deliveries: Kosugaya 1-20-6-202, Sakae-ku, 〒247-0007, Yokohama, JAPAN